Predictive Value of Soluble CD146 in Glioblastoma Patients

correlation between soluble CD146 plasma value and patient response (RANO)

Glioblastoma is the most common malignant primary brain tumor with poor prognosis because of
 its diffusive and infiltrative nature. The FDA approved the use of the anti-VEGF antibody
 bevacizumab in recurrent GBM. However, resistance to this anti-angiogenic reagent is frequent
 and fails to enhance patients' overall survival. The investigators previously identified one
 novel mechanism responsible for bevacizumab-resistance in CD146-positive glioblastoma
 (Joshkon et al. Acta Neuropathol Commun, 2022).
 
 Now, the investigators objective is to prospectively monitor the soluble CD146 value in
 plasma from patients treated by bevacizumab for recurrent glioblastoma.
 
 The investigators will collect plasma at baseline, before the first bevacizumab
 administration, before the second administration, at the time of first MRI evaluation and at
 progression. Plasma CD146 value will be analyzed by ELISA.
 
 The investigators expect to confirm the correlation between soluble CD146 value in plasma and
 patient response to bevacizumab.